Skip to menu Skip to content Skip to footer

2024

Journal Article

HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors

Tardiota, Nicolas, Jaberolansar, Noushin, Lackenby, Julia A., Chappell, Keith J. and O’Donnell, Jake S. (2024). HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors. Virology Journal, 21 (1) 14. doi: 10.1186/s12985-024-02288-z

HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors

2024

Journal Article

Human T-lymphotropic virus type 1 and antiretroviral therapy: practical considerations for pre-exposure and post-exposure prophylaxis, transmission prevention, and mitigation of severe disease

O’Donnell, Jake S., Jaberolansar, Noushin and Chappell, Keith J. (2024). Human T-lymphotropic virus type 1 and antiretroviral therapy: practical considerations for pre-exposure and post-exposure prophylaxis, transmission prevention, and mitigation of severe disease. The Lancet Microbe, 5 (4), e400-e408. doi: 10.1016/s2666-5247(23)00359-2

Human T-lymphotropic virus type 1 and antiretroviral therapy: practical considerations for pre-exposure and post-exposure prophylaxis, transmission prevention, and mitigation of severe disease

2023

Journal Article

Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma

O'Donnell, Jake S., Hunt, Stewart K. and Chappell, Keith J. (2023). Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma. The Lancet Haematology, 10 (7), e539-e548. doi: 10.1016/S2352-3026(23)00087-X

Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma

2022

Journal Article

Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine

O’Donnell, Jake S., Isaacs, Ariel, Jakob, Virginie, Lebas, Celia, Barnes, James B., Reading, Patrick C., Young, Paul R., Watterson, Daniel, Dubois, Patrice M., Collin, Nicolas and Chappell, Keith J. (2022). Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine. Frontiers in Immunology, 13 976968, 976968. doi: 10.3389/fimmu.2022.976968

Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine

2021

Journal Article

Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)?

O’Donnell, Jake S. and Chappell, Keith J. (2021). Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)?. Frontiers in Microbiology, 12 724654, 1-4. doi: 10.3389/fmicb.2021.724654

Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)?

2020

Journal Article

Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma

Lepletier, Ailin, Madore, Jason, O'Donnell, Jake S., Johnston, Rebecca L., Li, Xian-Yang, McDonald, Elizabeth, Ahern, Elizabeth, Kuchel, Anna, Eastgate, Melissa, Pearson, Sally-Ann, Mallardo, Domenico, Ascierto, Paolo A., Massi, Daniela, Merelli, Barbara, Mandala, Mario, Wilmott, James S., Menzies, Alexander M., Leduc, Charles, Stagg, John, Routy, Bertrand, Long, Georgina V., Scolyer, Richard A., Bald, Tobias, Waddell, Nicola, Dougall, William C., Teng, Michele W. L. and Smyth, Mark J. (2020). Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. Clinical Cancer Research, 26 (14), 3671-3681. doi: 10.1158/1078-0432.ccr-19-3925

Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma

Featured

2020

Journal Article

Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies

Chew, Hui Yi, De Lima, Priscila O., Gonzalez Cruz, Jazmina L., Banushi, Blerida, Echejoh, Godwins, Hu, Lingbo, Joseph, Shannon R., Lum, Benedict, Rae, James, O'Donnell, Jake S., Merida de Long, Lilia, Okano, Satomi, King, Brigid, Barry, Rachael, Moi, Davide, Mazzieri, Roberta, Thomas, Ranjeny, Souza-Fonseca-Guimaraes, Fernando, Foote, Matthew, McCluskey, Adam, Robinson, Phillip J., Frazer, Ian H., Saunders, Nicholas A., Parton, Robert G., Dolcetti, Riccardo, Cuff, Katharine, Martin, Jennifer H., Panizza, Benedict, Walpole, Euan ... Simpson, Fiona (2020). Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell, 180 (5), 895-914.e27. doi: 10.1016/j.cell.2020.02.019

Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies

2019

Journal Article

The promise of neoadjuvant immunotherapy and surgery for cancer treatment

O'Donnell, Jake S., Hoefsmit, Esmee P., Smyth, Mark J., Blank, Christian U. and Teng, Michele W.L. (2019). The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clinical Cancer Research, 25 (19), 5743-5751. doi: 10.1158/1078-0432.CCR-18-2641

The promise of neoadjuvant immunotherapy and surgery for cancer treatment

2019

Journal Article

Cancer immunoediting and resistance to T cell-based immunotherapy

O’Donnell, Jake S., Teng, Michele W. L. and Smyth, Mark J. (2019). Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology, 16 (3), 151-167. doi: 10.1038/s41571-018-0142-8

Cancer immunoediting and resistance to T cell-based immunotherapy

2019

Journal Article

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome

Liu, Jing, O’Donnell, Jake S., Yan, Juming, Madore, Jason, Allen, Stacey, Smyth, Mark J. and Teng, Michele W. L. (2019). Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. OncoImmunology, 8 (5) e1581530, 1-12. doi: 10.1080/2162402X.2019.1581530

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome

2018

Journal Article

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer

Ahern, Elizabeth, Harjunpää, Heidi, O'Donnell, Jake S., Allen, Stacey, Dougall, William C., Teng, Michele W. L. and Smyth, Mark J. (2018). RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. OncoImmunology, 7 (6) e1431088, e1431088. doi: 10.1080/2162402X.2018.1431088

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer

2018

Journal Article

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy

Liu, Jing, Rozeman, Elisa A., O’Donnell, Jake S., Allen, Stacey, Fanchi, Lorenzo, Smyth, Mark J., Blank, Christian U. and Teng, Michele W. L. (2018). Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. OncoImmunology, 8 (2) e1546068, 1-10. doi: 10.1080/2162402X.2018.1546068

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy

2017

Journal Article

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy

Glodde, Nicole, Bald, Tobias, van den Boorn-Konijnenberg, Debby, Nakamura, Kyohei, O'Donnell, Jake S., Szczepanski, Sabrina, Brandes, Maria, Eickhoff, Sarah, Das, Indrajit, Shridhar, Naveen, Hinze, Daniel, Rogava, Meri, van der Sluis, Tetje C., Ruotsalainen, Janne J., Gaffal, Evelyn, Landsberg, Jennifer, Ludwig, Kerstin U., Wilhelm, Christoph, Riek-Burchardt, Monika, Müller, Andreas J., Gebhardt, Christoffer, Scolyer, Richard A., Long, Georgina V., Janzen, Viktor, Teng, Michele W. L., Kastenmüller, Wolfgang, Mazzone, Massimiliano, Smyth, Mark J., Tüting, Thomas and Hölzel, Michael (2017). Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity, 47 (4), 789-802. doi: 10.1016/j.immuni.2017.09.012

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy

2017

Journal Article

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

O'Donnell, Jake S., Massi, Daniela, Teng, Michele W. L. and Mandala, Mario (2017). PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Seminars in Cancer Biology, 48, 91-103. doi: 10.1016/j.semcancer.2017.04.015

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

2017

Journal Article

Resistance to PD1/PDL1 checkpoint inhibition

O'Donnell, Jake S., Long, Georgina V., Scolyer, Richard A., Teng, Michele W. L. and Smyth, Mark J. (2017). Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treatment Reviews, 52, 71-81. doi: 10.1016/j.ctrv.2016.11.007

Resistance to PD1/PDL1 checkpoint inhibition

2016

Journal Article

Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease

Liu, Jing, Blake, Stephen J., Yong, Michelle C. R., Harjunpaa, Heidi, Ngiow, Shin Foong, Takeda, Kazuyoshi, Young, Arabella, O'Donnell, Jake S., Allen, Stacey, Smyth, Mark J. and Teng, Michele W. L. (2016). Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discovery, 6 (12), 1382-1399. doi: 10.1158/2159-8290.CD-16-0577

Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease

2016

Journal Article

The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer

Pera, Elena, Kaemmerer, Elke, Milevskiy, Michael J. G., Yapa, Kunsala T. D. S., O'Donnell, Jake S., Brown, Melissa A., Simpson, Fiona, Peters, Amelia A., Roberts-Thomson, Sarah J. and Monteith, Gregory R. (2016). The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer. Cancer Cell International, 16 (24) 24, 24. doi: 10.1186/s12935-016-0299-0

The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer